R&D GRIN Therapeutics: Seeking to address unmet needs in rare ne... Dr Bruce Leuchter, CEO of GRIN Therapeutics and Neurvati Neurosciences, discusses the companies GRIN-NDD work with pharmaphorum.
News Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.
News Germany will be first launch for PTC's phenylketonuria drug PTC Therapeutics' treatment for the rare disease PKU, Sephience, will launch in its first market next month after getting EU approval.
News Dupixent is first FDA-approved drug for rare skin disease The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.
News Biogen bids to extend use of Skyclarys to younger patients Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.
News Guidance creates access gap in UK for GPP drug Spevigo People in England and Wales with severe skin disease GPP will soon be able to access a new therapy currently denied to patients in Scotland.